Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed significantly compared to peers and the Nasdaq, especially during tighter monetary conditions, due to its concentrated portfolio and high valuation multiples. Virtus, with a more diversified and less concentrated portfolio, outperformed ARKG, suggesting that ARKG needs restructuring to better handle interest rate changes.
Ark Funds pull exclusively from different slivers of the technology sector that also tend to be the most volatile. Economic conditions can make a bigger performance difference over the long term than most investors might expect.
Wall Street roared back after a sell-off early in the month as fears of recession eased. The technology sector, which bore the biggest brunt, rebounded strongly and once again led the market over the past week.
July witnessed the "Great Rotation" in the U.S. stock market as investors shunned the hot technology stocks in favor of smaller companies and other sectors, which are the bigger beneficiaries of the Fed rate cuts.
Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's active management may not be outperforming compared to passive genomics ETFs like PBE, with potential regulatory and concentration risks.